Adhering to the strategic positioning of "microbiology, high technology and big industry", the Institute is committed to becoming an important national strategic scientific and technological force in the field of microbiology, aiming at the world's scientific and technological frontier, people's life and health and the sustainable development of economic and social, targeting the microbial groups of strategic significance. Around the microbial diversity and depth of mining resources and immune pathogenic microorganism infection and key prevention and control technology, forward-looking and strategic basic research and key technology research, efforts to promote the basic theory and key core technology breakthrough, driving the development of emerging industries, to achieve a high level of science and technology support and make a significant contribution.
Microbial provided early development state key laboratory of microbial resources, state key laboratory of mycology, state key laboratory of plant genomics () with the Chinese Academy of Sciences institute of genetics and developmental biology, microbial physiological and metabolic engineering, Chinese Academy of Sciences key laboratory, Chinese Academy of Sciences key laboratory of pathogenic microorganisms and immunology five key laboratory. In February 2020, the Engineering Laboratory of Agricultural Microbiology of the Chinese Academy of Sciences was established based on the Institute of Microbiology. At the same time, there are technical support platforms such as microbial resources and big data Center, technology transfer and transformation center, public platform of biosafety and animal experiments, public technology center of the university and a professional library. The Institute has also established the Center of Excellence in Biotechnology, the Center of Excellence in Research and Exchange of Emerging Infectious Diseases and the Influenza Research and Early Warning Center of the Chinese Academy of Sciences. The first National Microbiological Science Data Center (NMDC) and the internationally influential World Microbiological Data Center (WDCM) launched by the Ministry of Science and Technology and the Ministry of Finance are both located in the Institute. At the same time, the Institute has the China General Microbial Culture Preservation Management Center (CGMCC) with a storage capacity of more than 80,000 strains and the fungus Herbarium with a collection of more than 550,000 specimens.
During the 13th Five-Year Plan period, a series of achievements and progress have been made in the fields of cross-species transmission of emerging infectious diseases, microbial-host interaction, microbial technological innovation and resource utilization, and 2,135 high-level research papers have been published in Cell, Nature, Science and other journals. More than 525 domestic and international patents have been applied for, and more than 321 have been authorized. Research achievements on Ebola and COVID-19 were included in the "Top 10 Advances in Life Science in 2016" and "Top 10 Advances in Science in China in 2020". The recombinant novel coronavirus protein vaccine developed by the Institute has independent intellectual property rights and was the first approved for emergency use in China. The therapeutic antibody developed by the institute became the first specific drug to carry out clinical trials in China. These two achievements were selected as major scientific and technological achievements and landmark progress in the first phase of the "First Action" Program of the Chinese Academy of Sciences. The efficient synthesis of abamectin microorganisms won the second prize of the National Science and Technology Progress Award, and the pathogen room team won the "Qiushi" Outstanding Scientific and Technological Achievement Group Award and the National Innovation Prize.